🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

25 recruiting trials

for AML With Gene Mutations

A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in MDS/AML With TP53 Mutations NCT07646821Phase 1, Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: ropeginterferon alfa- 2b, Azacitidine (AZA) A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) NCT06852222Phase 3266 sites📍 Birmingham📍 Goodyear📍 Tucson Janssen Research & Development, LLC · Tests: Bleximenib, Venetoclax (VEN), Azacitidine (AZA), Placebo Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment NCT06696183Phase 21 site📍 Dresden Technische Universität Dresden · Tests: Gilteritinib (GILT), Venetoclax (VEN), Azacitidine (AZA) Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML NCT07500441n/a1 site📍 Beijing Peking University People's Hospital · Tests: Individualized Digital PCR (dPCR) monitoring Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML NCT05904106Phase 218 sites📍 Essen📍 Aachen📍 Augsburg Technische Universität Dresden · Tests: Venetoclax plus Azacitidine, standard of care chemotherapy plus gemtuzumab ozogamicin MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies NCT05735717Phase 21 site📍 Minneapolis Masonic Cancer Center, University of Minnesota · Tests: Fludarabine, Busulfan, Melphalan, Rituximab, Levetiracetam A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML NCT05735184Phase 144 sites📍 Phoenix📍 La Jolla📍 Los Angeles Kura Oncology, Inc. · Tests: Ziftomenib, Venetoclax, Azacitidine, Daunorubicin, Cytarabine a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia NCT07007949Phase 21 site📍 Suzhou The First Affiliated Hospital of Soochow University · Tests: Ivosidenib combined with venetoclax and azacitidine, Ivosidenib combined with venetoclax and azacitidine Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants NCT07019155n/a1 site📍 Bethesda National Cancer Institute (NCI) Personalized NK Cell Therapy in CBT NCT02727803Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Busulfan, Clofarabine, Cyclophosphamide A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations NCT04293562Phase 3206 sites📍 Birmingham📍 Mobile📍 Mesa Children's Oncology Group · Tests: Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Mar… Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia NCT06366789Phase 123 sites📍 Los Angeles📍 San Francisco📍 Atlanta Lomond Therapeutics Holdings, Inc. · Tests: ZE46-0134 Study of Families With an Hemopathies Predisposition Related to the DDX41 Gene. NCT06022016NA5 sites📍 Bordeaux📍 Limoges📍 Marseille Institut Claudius Regaud · Tests: For each person (index case or related) included in this study: Revumenib in Combination With 7+3 + Midostaurin in AML NCT06313437Phase 12 sites📍 New Haven📍 Boston Richard Stone, MD · Tests: Revumenib, Midostaurin, Cytarabine, Daunorubicin Study for Characterisation of Predictive Parameters of Clonal Evolution in Subjects With GATA2 Germline Mutation NCT05983991NA24 sites📍 Angers📍 Bordeaux📍 Caen Institut Claudius Regaud · Tests: Biological samples (blood and bone marrow samples). Oral-ATO for TP53-mutated Myeloid Malignancies NCT06778187Phase 21 site📍 Hong Kong The University of Hong Kong · Tests: Oral arsenic trioxide A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation NCT04065399Phase 1, Phase 257 sites📍 Duarte📍 Los Angeles📍 Palo Alto Syndax Pharmaceuticals · Tests: revumenib, cobicistat Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients NCT07507760Phase 220 sites📍 Aveiro📍 Funchal📍 Lisbon PETHEMA Foundation · Tests: Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET, Ivosidenib Oral Tablet, Hydroxyurea, Cytarabine, Allogeneic stem cell… A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid Leukemia NCT07028073Phase 1, Phase 21 site📍 Suzhou The First Affiliated Hospital of Soochow University · Tests: Group A (FIT): Avapritinib + IA regimen, Group B (UNFIT): Avapritinib + VA regimen Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome NCT03383575Phase 23 sites📍 Baltimore📍 Cleveland📍 Houston M.D. Anderson Cancer Center · Tests: Azacitidine, Enasidenib, Quality-of-Life Assessment Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation NCT03683433Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Azacitidine, Enasidenib Mesylate Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia NCT06549790Phase 17 sites📍 Duarte📍 Aurora📍 Newark Nerviano Medical Sciences · Tests: NMS-03597812 CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome NCT04493164Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Ivosidenib, Liposome-encapsulated Daunorubicin-Cytarabine A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML NCT07751991Phase 15 sites📍 Duarte📍 New Haven📍 Grand Rapids Charm Therapeutics · Tests: CHM-029 The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation NCT06561880Phase 1, Phase 21 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: Venetoclax, Cytarabine, Gilteritinib, Azacitadine (AZA)
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy